Roxatin Tablet 20 mg

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

ROSUVASTATIN CALCIUM

Boleh didapati daripada:

PHARMANIAGA MANUFACTURING BERHAD

INN (Nama Antarabangsa):

ROSUVASTATIN CALCIUM

Unit dalam pakej:

30 Tablets

Dikeluarkan oleh:

PHARMANIAGA MANUFACTURING BERHAD

Risalah maklumat

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
ROXATIN TABLET
Rosuvastatin Calcium (10mg / 20mg)
_ _
1
WHAT IS IN THIS LEAFLET
1.
What Roxatin Tablet is used for
2.
How Roxatin Tablet works
3.
Before you use Roxatin Tablet
4.
How to use Roxatin Tablet
5.
While you are using Roxatin
Tablet
6.
Side effects
7.
Storage and disposal of Roxatin
Tablet
8.
Product description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of Revision
WHAT ROXATIN TABLET IS USED FOR
You have been prescribed Roxatin
because:
a)
You
have
a
high
cholesterol
level. This means you are at risk
of getting a heart attack or stroke.
You have been advised to take a
statin,
because
changing
your
diet
and
taking
more
exercise
were not enough to correct your
cholesterol
levels.
You
should
continue with your cholesterol-
lowering diet and exercise while
you are taking Roxatin. Or
b)
You
have
other
factors
that
increase your risk of getting a
heart
attack,
stroke
or
related
health problems.
Heart
attack,
stroke
and
other
problems
can
be
caused
by
a
disease called atherosclerosis.
Atherosclerosis is due to build-
up
of
fatty
deposits
in
your
arteries.
HOW ROXATIN TABLET WORKS
Roxatin is used to correct the levels
of
fatty
substances
in
the blood
called lipids, the most common of
which is cholesterol.
There
are
different
types
of
cholesterol
found
in
the
blood,
including ‘bad’ cholesterol (LDL-
C) and ‘good’ cholesterol (HDL-
C).
•
Roxatin
can
reduce
the
‘bad’
cholesterol
and
increase
the
‘good’ cholesterol.
•
It works by helping to block your
body’s
production
of
‘bad’
cholesterol
in
the
liver.
It
also
improves your body’s ability to
remove it from your blood.
For most people, high cholesterol
does not affect the way they feel
because it does not produce any
symptoms. However, if it is left
untreated, fatty deposits can build
up
in
the
walls
of
your
blood
vessels causing them to narrow.
Sometimes, these narrowed blood
vessels can get blocked which can
cut off the blood supply to the
heart or brain leading to a he

Ciri produk

ROXATIN TABLET 10 MG
ROXATIN TABLET 20 MG
COMPOSITION
Roxatin Tablet 10 mg
Each film coated tablet contains 10mg Rosuvastatin (as calcium salt)
Roxatin Tablet 20mg
Each film coated tablet contains 20mg Rosuvastatin (as calcium salt)
DESCRIPTION
Roxatin Tablet 10 mg
Round (7 mm), light brick red biconvex film-coated tablet with
Pharmaniaga icon on one side
and plain on the other.
Roxatin Tablet 20mg
Round (9.5 mm), light brick red, biconvex film-coated tablet with
Pharmaniaga icon on one
side and plain on the other.
PHARMACODYNAMICS
Rosuvastatin is a selective, potent and competitive inhibitor of
HMG-CoA reductase, the
rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme
A to mevalonate, a
precursor of cholesterol. Triglycerides (TG) and cholesterol in the
liver are incorporated, with
apolipoprotein B (ApoB), into very low density lipoprotein (VLDL) and
released into the plasma
for delivery to peripheral tissues. VLDL particles are TG-rich.
Cholesterol-rich low density
lipoprotein (LDL) is formed from VLDL and is cleared primarily through
the high affinity LDL
receptor in the liver.
Rosuvastatin produces its lipid-modifying effect in two ways; it
increases the number of
hepatic LDL receptors on the cell-surface, enhancing uptake and
catabolism of LDL and it
inhibits the hepatic synthesis of VLDL, thereby reducing the total
number of VLDL and LDL
particles.
High density lipoprotein (HDL), which contains ApoA-I is involved,
amongst other things, in
transport of cholesterol from tissues back to the liver (reverse
cholesterol transport).
The involvement of LDL-C in atherogenesis has been well documented.
High LDL-C, TG, low
HDL-C and ApoA-I have been linked to a higher risk of cardiovascular
disease. Available data
have shown the benefits on mortality and CV event rates of lowering
LDL-C and TG or raising
HDL-C. More recent data has linked the beneficial effects of HMG-CoA
reductase inhibitors to
lowering of non-HDL (i.e. all circulating cholesterol not in HDL) and
ApoB or reducing the
ApoB/ApoA-I ra